Valuation : Positron Corporation

Market Cap 53.54M 46.1M 43.28M 39.51M 74.22M 5.09B 74.76M 513M 200M 2.58B 201M 197M 8.55B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 52.4M 45.12M 42.36M 38.67M 72.65M 4.99B 73.17M 502M 195M 2.53B 197M 192M 8.37B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 2018-02-26
Sales & Marketing - 2022-06-23
Corporate Officer/Principal 40 2018-05-24
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.42%-26.30%-4.82% 12.82B
+4.24%-2.30%+14.39%+9.32% 4.41B
+1.69%-4.06%-39.90%-56.34% 1.23B
-0.27%-0.90%-37.68%-41.10% 1.16B
-0.79%-0.92%+20.60%+86.85% 1.11B
+1.52%+0.30%-36.15% - 1.05B
-0.79%+7.35% - - 1.04B
-0.19%-3.87%+28.33%+109.66% 536M
-1.52%+0.17%+60.00% - 297M
Average +0.32%+0.89%-2.09%+17.26% 2.63B
Weighted average by Cap. +0.29%-0.40%-15.42%+0.83%

Financials

2024 2025
Net sales 588K 506K 475K 434K 814K 55.9M 820K 5.63M 2.19M 28.35M 2.21M 2.16M 93.86M 461K 397K 373K 341K 640K 43.91M 644K 4.42M 1.72M 22.26M 1.73M 1.69M 73.72M
Net income -2.38M -2.05M -1.92M -1.76M -3.3M -226M -3.32M -22.79M -8.87M -115M -8.93M -8.74M -380M -10.6M -9.13M -8.57M -7.83M -14.7M -1.01B -14.81M -102M -39.52M -512M -39.81M -38.95M -1.69B
Net Debt 1.42M 1.23M 1.15M 1.05M 1.97M 136M 1.99M 13.65M 5.31M 68.73M 5.35M 5.23M 228M -1.14M -978K -919K -838K -1.58M -108M -1.59M -10.88M -4.23M -54.82M -4.27M -4.17M -182M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-